m****u
发帖数: 275 | 1 It depends on the type of lymphoma and the expertise of the pathologists.
The flow cytometry report lz posted is apparently incomplete and the person
who reported it was not competent. At least the person could have looked at
whether pan-T cell antigens are decreased or increased instead of reporting
them as + or -, which is not very helpful. The CD4/CD8 is 117, that's very
abnormal, whey did they not look into it? If they saw 12% of cells
expressing CD30, they should go further to see whether t... 阅读全帖 |
|
m**********t
发帖数: 19 | 2 This drug specifically targets to CD30. So it works better for patients who
are CD30 positive. It is almost not possible to purchase this drug directly.
The US physicians do not write subscription for patients aboard unless they
are here. Also, since this is an antibody drug which needs to be transported
in 2-8 degree cool box, without professional service, you will not be able
to bring them back to China.
Do not buy this drug online. It is just too much risk. Most of the top level
oncologists i... 阅读全帖 |
|
w***u
发帖数: 17713 | 3 二线药就得在二线才能用，但是医生可以有自己的判断offlabel,他这种情况要跳出
guideline也不太可能。他必须CD30+阳性。这个药其实是把化疗药连在抗体上，抗体起
的是找到CD30+阳性的白细胞上，然后抗体释放化疗药，实现病灶给药，降低化疗副作
用，提高细胞毒性。 |
|
l******i
发帖数: 17 | 4 Adcetris(brentuximab vedotin) 是一种治疗 anaplastic large cell lymphoma (
ALCL) and Hodgkin lymphoma 的新药. 它是抗CD30 的单抗上面连接了抑制细胞分裂的
药物, 理论上减轻毒副作用,增强定位效果. 因为Hodgkin lymphoma is B cell
lymphoma expressing CD30, Adcetris 起到了靶向治疗的目的.
My cousin several years ago also had lymphoma (non-Hodgkin's), he got cured
by doctors at Standford. Male patients with early onset lymphoma should have
better prognosis. Important thing is to find a great doctor with
sophisticated experience.
May God bless him. |
|
|
f******2
发帖数: 1027 | 6 在中国的一个朋友两个月前觉得身体不舒服，检查，发现脾脏上有个肿瘤，手术切除脾
脏后，做病理，说是淋巴瘤。进行了网络查询和医生咨询，说是原发于脾脏的淋巴瘤很
罕见。目前在医院接受进一步的化疗，考虑到这个病例的少见，医生提出的化疗方法甚
至缺少参照的依据，不知各位是否有这方面的经验？
我朋友目前在中国的方案是R+CHOP，这个是针对一般的NHL淋巴瘤的，但是针对脾脏原
发性的淋巴瘤，各位是否知道美国有比中国更好的方案吗？
这个是一些检测的结果和数据：
（脾）弥漫性大B细胞淋巴瘤（生发中心来源）
残留脾组织红髓血窦扩张充血，白髓萎缩，小动脉（中央A）管壁增厚，透明变性。
（肝）海绵状血管瘤
免疫组化： CD20,PAX-5(+),CD10,Bc1-6,Mum-1(+);
CD2,CD3,CD5,CD7,CD30,ALK(-);
Ki-67:70%(+) |
|
m****u
发帖数: 275 | 7 You likely have a CD30+ T cell lymhoma. The flow cytometry was not read
properly. I would recommend you to have a biopsy with flow cytometry and
histology done asap. Its better to have it done in the USA but insurance may
be a problem since the diagnostic fees alone will be in the thousands. Go
to a better hospital in China. |
|
l****s
发帖数: 161 | 8 what is cd30+ t cell lymphoma? is this curable? or is the survival chance
high?
many thanks!
may |
|
m****u
发帖数: 275 | 9 I am a hematopathologist. The flow cytometry report was incomplete. I was
surprised how low-profile Fudan medical center is. However, based on the
information you pasted, you likely have a CD30+ T cell lymphoma or Hodgkin'
s lymphoma. I would suggest you seek a biopsy of the lymph node for
definitive diagnosis. Lymphoma is hematologic malignancy. Once diagnosed,
you will receive chemotherapy. The prognosis will depend on the lymphoma
type and staging. Do not waste time here, go to get an excisi... 阅读全帖 |
|
T**7
发帖数: 264 | 10 请发给我：
你的
（1）简短的PUBLICATION LIST
不超过5篇文章
（2）你的名字
（3）学位
（4）EMAIL地址
谢谢
entitled "Serum soluble CD30 - a marker of airways inflammation in multiple-
trigger wheezers?"
Article Type: Original Article
Background: Imbalance in activation of T-helper cell types 1 (Th1) and 2 (
Th2) may have a link with the development of asthma. Objective: To evaluate
the role of serum soluble markers of Th1- and Th2-lymphocyte activation with
regard to lung function, inflammatory markers, and therapy response in 90
pre... 阅读全帖 |
|
m*********3
发帖数: 1425 | 11 刘伯宁
http://blog.sciencenet.cn/home.php?mod=space&uid=454912&do=blog
今年上半年，美国FDA先后批准两种抗体-药物偶联剂（Antibody-drug conjugates，以
下简称ADCs药物）上市，分别为Seattle Genetics公司的Adcetris TM和罗氏公司的
Kadcyla™。与此同时，据《自然·药物发现》杂志统计，2009-2010年共有7种
ADCs药物，2011-2012年至少有17种ADCs药物进入临床研究阶段。目前，在世界范围内
进入临床研究的ADCs药物累计已达三十余种。ADCs候选药物在数量上已经超过同为“改
型抗体”的双特性抗体、抗体片段等类别，成为单克隆抗体药物，尤其是肿瘤治疗用单
抗的研究热点与发展方向。
ADCs药物的概念由来
单克隆抗体用于肿瘤靶向治疗的概念由来已久。一百年多前，德国免疫学家保罗·欧立
希（Paul Ehrlich）最早提出单克隆抗体的“黄金子弹”学说，即：利用单克隆抗体对
抗原的特异性结合实现对癌变细胞的靶向治疗。同时，保罗·欧立希也是临床上化学... 阅读全帖 |
|
m*********3
发帖数: 1425 | 12 刘伯宁
http://blog.sciencenet.cn/home.php?mod=space&uid=454912&do=blog
今年上半年，美国FDA先后批准两种抗体-药物偶联剂（Antibody-drug conjugates，以
下简称ADCs药物）上市，分别为Seattle Genetics公司的Adcetris TM和罗氏公司的
Kadcyla™。与此同时，据《自然·药物发现》杂志统计，2009-2010年共有7种
ADCs药物，2011-2012年至少有17种ADCs药物进入临床研究阶段。目前，在世界范围内
进入临床研究的ADCs药物累计已达三十余种。ADCs候选药物在数量上已经超过同为“改
型抗体”的双特性抗体、抗体片段等类别，成为单克隆抗体药物，尤其是肿瘤治疗用单
抗的研究热点与发展方向。
ADCs药物的概念由来
单克隆抗体用于肿瘤靶向治疗的概念由来已久。一百年多前，德国免疫学家保罗·欧立
希（Paul Ehrlich）最早提出单克隆抗体的“黄金子弹”学说，即：利用单克隆抗体对
抗原的特异性结合实现对癌变细胞的靶向治疗。同时，保罗·欧立希也是临床上化学... 阅读全帖 |
|
w*******y
发帖数: 60932 | 13 DiscountMags offers a 1-Year Subscription to China Daily for $99. Coupon
code "CD30" makes it $30. That's $530 off a subscription purchased directly
from China Daily and the lowest price we could find. It includes a total of
258 issues.
Link:
http://www.discountmags.com/product/10039
|
|
